LOGIN  |  REGISTER
Amneal Pharmaceuticals
Compass Therapeutics

Globus Medical to participate in the Canaccord Genuity 2025 Musculoskeletal Conference

March 05, 2025 | Last Trade: US$58.28 0.58 -0.99

AUDUBON, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it is scheduled to participate in the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego. Management is scheduled to present on Monday, March 10, 2025 at 4:30 pm PT.

Interested parties can access the live and archived webcast of the presentation in the “News & Events”, “Events & Webcasts” section of the Globus Medical investor relations website at https://www.investors.globusmedical.com/news-events/events-webcasts.  

About Globus Medical, Inc. 

Based in Audubon, Pennsylvania, Globus Medical, Inc. is a leading global musculoskeletal technology company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, regenerative biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com.  

Investor contact: 
Brian Kearns 
610-930-1800 
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media contact: 
Moran Chavez 
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page